Analyst Soumit Roy of JonesTrading maintained a Buy rating on Mural Oncology Plc (MURA – Research Report), retaining the price target of $16.00.
Soumit Roy has given his Buy rating due to a combination of factors surrounding Mural Oncology Plc’s promising developments. The primary focus is on the upcoming interim survival data from the ARTISTRY-7 Phase 3 trial, which is investigating the efficacy of nemvaleukin in combination with Keytruda for treating platinum-resistant ovarian cancer. Positive results from this trial, expected in the first half of 2025, could significantly enhance investor confidence and potentially lead to a Biologics License Application (BLA) filing by the third quarter of 2025 and possible approval by mid-2026.
Roy highlights the potential of nemvaleukin as a differentiated IL-2 fusion protein that mitigates adverse effects commonly associated with this drug class while activating tumor-killing immune cells. The report outlines three potential outcomes from the trial, with the most favorable scenario leading to a substantial increase in stock value. Additionally, the management’s plan to present detailed trial data at a medical conference further supports the positive outlook for Mural Oncology Plc, reinforcing the Buy rating.
In another report released on March 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com